At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 127 enrolled
Drug / intervention
Etanerceptdrug
Likely dose
Etanercept 0.8 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 2-Part Open-Label Study to Assess the Clinical Benefit and Long-Term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, or Psoriatic Arthritis
In Brief
A Phase 3 clinical trial evaluating Etanercept for Arthritis, Juvenile Idiopathic. Completed, enrolled 127 participants across 42 sites in 19 countries.
Detailed Summary
This study will evaluate the effect of etanercept on the clinical benefit, safety, and physical functioning (ability to function in daily life) in children and adolescent subjects with 3 subtypes of childhood arthritis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis, Juvenile Idiopathic
CountriesAustralia, Belgium, Colombia, Czechia, France, Germany, Hungary, Italy, Latvia, Lithuania, Mexico, Netherlands, Norway, Poland, Russia, Serbia, Slovakia, Slovenia, Spain
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2009
Enrollment StartSep 2009
Primary CompletionJun 2011
Study CompletionJan 2013
TodayJul 2026
First PostedAug 20, 2009
Enrollment StartSep 1, 2009
Primary CompletionJun 1, 2011
Study CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 16.9 years ago
Interventions
Etanerceptdrug
Etanercept 0.8 mg/kg QW up to a maximum dose of 50 mg